
From the country of turtlenecks | Quant. biology | Biobuilding @orakldotbio | Former @institutpasteur @Cambridge_Eng @Polytechnique | 🇫🇷 🇸🇪 🇪🇺
Paris, Frankreich
Joined May 2012
- Tweets2.8K
- Following757
- Followers392
- Likes6.1K
🧬 Everyone has their favorite omics-based foundation model, but comparing them is difficult, and more often then not the performance on your own dataset is underwhelming.
Yesterday, @ScientaLab, @huggingface and @orakldotbio launched PRIMO to solve this.
Omics foundation models are multiplying, but the field needs a shared way to measure what they bring to drug development.
Today, @ScientaLab, @orakldotbio and @huggingface are launching PRIMO.
PRIMO (Patient Representations in Multi-Omics) is an open benchmark that evaluates omics foundation models on real drug development tasks, using real patient cohorts.
Current evaluations, such as reconstruction, cell-type annotation or batch integration, are valuable, but they leave one question open for anyone building drugs: does a model's patient representation actually carry clinically useful signal?
PRIMO currently evaluates:
- 70 tasks across 50 patient cohorts (5,000+ patients) and 4 therapeutic areas
- Treatment response, prognosis, disease severity, molecular subtypes
- Separate bulk and single-cell leaderboards
- Zero-shot representations, with labels held out
We already have 40+ models evaluated on the leaderboards, let's submit your model and see how it ranks if you have one: huggingface.co/spaces/PRIMOm…
And if you're in Paris during NeurIPS, come talk about it in person.
We're hosting a AI in Bio social with @biolabs and @orakldotbio on December 11 at the Hôtel-Dieu, where we'll introduce PRIMO. Register here: luma.com/3gube2sv
PRIMO is a benchmark focused on clinically relevant outcomes with most of the leading published models on it and looking at zero-shot predictions.
Your favorite model is missing? Submissions are open huggingface.co/spaces/PRIMOm…
1
1
83
We're also doing a cool event for #neurips2026 co-hosted with @ScientaLab and BioLabs. DM me if interested!
1
74
Gustave Ronteix retweeted
We proudly gave @OpenAI our NVIDIA DGX-1 supercomputer to work on #AI's toughest problems. nvda.ws/2aRtOhE
Gustave Ronteix retweeted
Congrats to the incredible folks at Orakl Bio!! Super impressive and determined team fighting the good fight against cancer.
We just raised a $34M Series A at @orakldotbio, co-led by @NorrskenVC and @singular__.
AI has become remarkably good at designing molecules. Yet most cancer drugs still fail in clinical trials.
Here's why, and what we're doing about it 🧵
We just raised a $34M Series A at @orakldotbio, co-led by @NorrskenVC and @singular__.
AI has become remarkably good at designing molecules. Yet most cancer drugs still fail in clinical trials.
Here's why, and what we're doing about it 🧵
What the $34M funds:
→ New models on a proprietary dataset 5× larger
→ Lung and gastric cancers, beyond colorectal and pancreatic
→ Target discovery, directly from patient biology
1
197
Gustave Ronteix retweeted
Today, we release the weights of a new and improved Le Chonk, advancing the open frontier for agentic coding and cybersecurity.
💻 Built to build: Le Chonk ranks #1 on @cognition’s FrontierCode among open models, and sets a new benchmark for Pareto efficiency on @artificialanalysis.
🛡 Built to defend: State-of-the-art in cyberdefense, put through the paces by the world's leading cyber vendors, including @CrowdStrike, @cloudflare, @rubrik, @zscaler, and others.
Built for sovereignty: Make it yours. Download the weights on @huggingface , customize it with Mistral Forge, and deploy it wherever you need it.
Read more from our team and customers 👇:
Gustave Ronteix retweeted
Should Europe leave frontier AI to the Americans and the Chinese?
The idea has gained ground in Europe. It is a fundamental mistake.
Build or surrender: for now, the choice is still ours.
Full article below.
Gustave Ronteix retweeted
The real world abounds with recursively self-improving systems, but one in particular deserves attention: Science, modeled as a system (perhaps even as an agent, with goals and resources). If you want to really understand AI RSI, science should be your reference point.
Science is an intelligent system, and it is obviously recursively self-improving:
1. Scientific discoveries unlock new technology that helps build better experimental tools. This is a top driver of progress in nearly all fields.
2. They unlock new conceptual advances (ideas, theories) that help solve more problems.
3. They increase society's economic output, leading to more resources flowing into science.
4. They unlock better faster tooling (e.g. more compute via better chip & networking technology).
As a result, many measures of scientific *input* grow exponentially:
1. Headcount (doubles every ~15 years)
2. Global R&D spending (doubles a bit faster, every ~13 years)
3. Papers and patents (technically this is a measure of headcount)
4. Compute dedicated to science (doubles every ~2 years)
But is scientific progress exponential? Historically, the rate of scientific impact over time has remained roughly constant since the start of the industrial revolution (i.e. scientific progress is *linear*). 1850-1900 was about as dramatic as 1900-1950 or 1950-2000.
1850–1900: Evolution, germ theory & antiseptic surgery, thermodynamics, electromagnetic field equations, the periodic table, pharmaceuticals, electricity, telegraph and telephone, internal combustion engine, skyscrapers, mechanized agriculture...
1900–1950: special and general relativity, quantum mechanics, nuclear fission & atomic energy, antibiotics, genetic theory, electronic computers, information theory, synthetic polymers and plastics, the transistor, aviation...
1950–2000: DNA, genetic engineering, integrated circuits, microprocessors & personal computing, the Internet, crewed spaceflight, moon landing, satellite communications & GPS, standard model of particle physics...
In real terms, like life expectancy, which has increased in a remarkably linear fashion of roughly 3 months per year since 1840, progress is a straight line. This is especially apparent for fields where impact is easy to measure, like biology, medicine, and agriculture.
I first wrote about this phenomenon and its causes in 2012, and a steady stream of research has confirmed it in the years since. Examples include the 2018 paper by Nielsen and Collison, "Science Is Getting Less Bang for Its Buck," and the 2020 economic paper, "Are Ideas Getting Harder to Find?" (In fact, I believe the Nielsen paper stemmed from a conversation I had with him about this exact idea six months earlier)
In short, the primary cause is that research solves the highest-impact, easiest problems first, and every subsequent problem is either harder or lower-impact. Exponentially so. The paper that presented information theory wasn't very hard to write (single author!) but you'd have a hard time ever writing a CS paper that beats it in impact.
This is why science as a system requires exponential resources (input) to produce linear impact (output). It gets exponentially harder over time.
Worth thinking about if you're pondering RSI for AI. I fully believe AI RSI is already happening and will accelerate in the future. But I do not believe this leads to an "intelligence explosion" -- that would fly in the face of everything I know about intelligence and everything I know about recursively self-improving systems.
Gustave Ronteix retweeted
Meet Mistral Large 4, aka Le Chonk.
• 1T parameters, natively multimodal. 49B active.
It is the best open weights model from US or Europe on aggregated benchmarks.
• State-of-the-art on critical workloads, including cyber defense, manufacturing and finance and it surpasses closed frontier models on visual grounding.
• Forged in Europe end-to-end and is deployable from Europe via our own Mistral Cloud infrastructure.
• Available to all via API today. Working with cybersecurity partners privately.
Open weights release end of October.
🤖 Made with AI
Gustave Ronteix retweeted
Super stoked to show what the @tychobio_ai team is cooking here !
Let the high-quality data flow ;)
We’re excited to announce a new collaboration with @tychobio_ai to advance AI-driven RNA therapeutics for rare disease.
PacBio HiFi + Kinnex sequencing will generate full-length RNA data from 10,000+ samples to help train AI drug discovery models.
🔗 bit.ly/4AVHK0A
Gustave Ronteix retweeted
McKinsey out today on AI drug discovery — "focusing on what matters most." The framing is right. Most AI in pharma is still applied to the easy parts. The hard part is target biology and clinical translation. mckinsey.com/industries/life…
Gustave Ronteix retweeted
Ordinary Abundance. This is the greatest thing I've read in weeks. No kidding. This should win a Pulitzer in a category not yet invented. ordinaryabundance.com/














